The serrated pathway is a distinct pathway of colorectal carcinogenesis that has been implicated in development of a substantial proportion of interval colorectal cancers. The fecal immunochemical test (FIT) detects early neoplasms with a higher level of sensitivity than the guaiac test. We investigated the sensitivity of the FIT in detection of sessile serrated adenomas/ polyps (SSA/Ps).
trials, the likelihood of detecting an invasive cancer with a positive guaiac fecal occult blood test (gFOBT) was 8-25 times greater than primary screening colonoscopy without a priori test. 2 Fecal immunochemical test (FIT) has been shown to outperform gFOBT for detecting early advanced neoplasms, with comparable specificity and higher public acceptance. 3 In addition, recent studies have shown higher screening uptake level for FIT than for colonoscopy, making FIT one of the most popular noninvasive CRC screening tests worldwide, especially in regions with limited resources or constrained endoscopy manpower. 4 Recent studies of FIT sensitivity for CRC, advanced adenoma, and non-advanced adenoma reported values of 79%, 32%, and 21.4%, respectively. [5] [6] [7] CRCs occurring after negative FITs arise mainly because of either insufficient sensitivity of FIT for existent neoplasms or new, rapidly growing neoplasms that arise after the previous screening round. 8 However, the sensitivity of FIT for sessile serrated adenoma/polyp (SSA/P) remains uncertain. Heigh et al 9 reported the performance of FIT in a study involving 29 patients with SSA/Ps larger than 10 mm and found sensitivities of 0% and 10% with cutoffs of 20 and 10 mg hemoglobin/g feces, respectively. Another study by Imperiale et al 10 also demonstrated that FIT had low sensitivity for large SSA/Ps, with 5.1% at 20 mg/g. There are limited data regarding FIT performance for SSA/P detection. The present study aimed to determine the sensitivity of FIT for SSA/P in a large screening population at different cutoff values.
Materials and Methods

Study Participants and Ethical Considerations
In this prospective study, subjects were selected by screening a consecutive series of patients 50 years or older who had submitted to health checkups in National Taiwan University Hospital between August 2010 and November 2014. The health checkup program included FIT screening in addition to screening colonoscopy. Only ethnic Chinese patients who had received total colonoscopy were included. Average risk was defined as those who did not receive any CRC screening tests during the previous 10 years. Those with a personal history of CRC or colectomy, hereditary polyposis, or inflammatory bowel disease were excluded from this study (Figure 1 ). Before undergoing health evaluation and colonoscopy, all participants were asked to complete and submit a standard questionnaire as described in our previous studies. [11] [12] [13] Before implementation, this study received approval (no. 200904069R) from the institutional review board and the ethical committee of our institute.
Colonoscopy
The details of colonoscopy, including preparation and instruments, agree with those described in detail in previous studies. 12, 14 All endoscopists involved in this study had experience in performing at least 5000 colonoscopies and were familiar with the techniques of chromoendoscopy (CE), narrow band imaging (NBI), and magnifying observation. Conventional white-light endoscopy observation was followed by 2 image-enhanced endoscopy modalities, NBI and CE. All the endoscopists were blinded to the FIT results. Results of all polyps detected, their number, size, morphology, anatomic location, and endoscopic diagnoses were recorded. All resected lesions were sent for histopathologic assessment.
Fecal Immunochemical Test
Single stool sample with quantitative FIT test with OC-SENSOR kit (Eiken Chemical Co, Ltd, Tokyo, Japan) was used in this study, and we tested 3 different fecal hemoglobin cutoffs, 10, 15, and 20 mg/g feces, for determining FIT positivity. All patients were asked to collect the fecal samples at home by using the collecting stick, to refrigerate the samples during storage, within 2 days before colonoscopy, and to submit the samples on the day of colonoscopy. The submitted fecal samples were then sent to the central clinical laboratory in our institute for assay on the same day. The laboratory technologists were blinded to the colonoscopy findings.
Histologic Diagnosis
A colon neoplasm, including conventional adenoma and serrated lesion, was classified according to World Health Organization criteria. 15 Advanced adenoma was defined as a lesion 10 mm or larger in diameter or a lesion with a villous component or high-grade dysplasia. All preliminarily diagnosed and endoscopically resected serrated polyps were verified and classified by a dedicated gastrointestinal pathologist who was not aware of the endoscopic findings. The histologic classification of serrated polyps followed the World Health Organization criteria. 15, 16 A large serrated polyp refers to SSA/P or hyperplastic polyp sized 10 mm or larger in diameter.
Statistical Analysis
The sensitivity of FIT for various lesion categories was analyzed by using the cutoffs of 10, 15, and 20 mg/g, respectively. The sensitivity for large serrated polyp, including both SSA/P and large hyperplastic polyp, was also calculated, because some large hyperplastic polyps were likely SSA/Ps. 17 Positive predictive values (PPVs) and the number needed for endoscopy (NNScope) were calculated for each category of lesion. A post hoc analysis of FIT positivity for different patient and lesion characteristics was analyzed with several logistic regression models comparing SSA/P versus conventional adenoma, adjusting for patients' age, gender, smoking status, medication use (antiplatelet agent or nonsteroidal antiinflammatory drugs [NSAIDs]), body mass index, cecal intubation, and bowel cleansing level by using Aronchick 4-level scale. When the model was used to compare large SSA/P with advanced adenoma, an additional adjustment was made to account for lesion size. Values of P < .05 were considered statistically significant. Statistical analysis was conducted by using SPSS statistical package, version 17.0 (IBM Corp, Armonk, NY).
Results
Patient Demographic and Clinical Information
The demographic and clinical characteristics of the study cohort are presented in Table 1 . The study consisted of 6198 patients (mean age, 59.0 AE 7.0 years), 3165 of whom (51.1%) were male. Prevalence of SSA/P, non-advanced adenoma, and advanced adenoma in the study cohort was 1.4%, 20.2%, and 5.5%, respectively. The overall cecal intubation rate was 99.3%, and poor bowel preparation rate was 8.9%. The patients with poor bowel preparation were excluded from this study as incomplete colonoscopy. There were 10.4% of patients who had a prior colonoscopy more than 5 years ago; therefore, 89.6% of patients were average risk. Also, 2.9% of patients had history of adenoma.
Diagnostic Performance of Fecal Immunochemical Test for Sessile Serrated Adenoma/Polyp
FIT sensitivity for different lesion categories at different cutoffs is summarized in Table 2 . The sensitivity of FIT for SSA/P was 12.3% (95% confidence interval [CI], 5.8%-23.4%) at a cutoff of 10 mg/g, 6.2% (95% CI, 2.0%-15.8%) at 15 mg/g, and 6.2% (95% CI, 2.0%-15.8%) at 20 mg/g. The sensitivity for large SSA/P only was 18.4% (95% CI, 8.3%-34.9%), 10.5% (95% CI, 3.4%-25.7%), and 10.5% (95% CI, 3.4%-25.7%), respectively, at those 3 cutoffs. The FIT sensitivity for synchronous SSA/P and conventional adenoma was slightly higher than SSA/P alone. However, the difference was not significant, and the P values were .972, .760, and .870, respectively, at those 3 cutoffs. FIT sensitivity for SSA/P in association with lesion location is shown in Table 3 . The sensitivity for proximal and distal SSA/P with no synchronous conventional adenoma was 10.6% (95% CI, 4.0%-23.9%) and 16.7% (95% CI, 4.4%-42.3%), respectively, at the cutoff value of 10 mg/g. For large SSA/P with no synchronous conventional adenoma, the sensitivity at proximal and distal colon was 16.1% (95% CI, 6.1%-34.5%) and 28.6% (95% CI, 6.8%-32.7%), respectively, at the cutoff value of 10 mg/g. Sensitivity for distal or large distal SSA/P was higher than that for proximal or large proximal SSA/P. A similar trend was also observed when comparing proximal and distal SSA/P with synchronous conventional adenoma at a cutoff of 10 mg/g.
Multivariate Analysis of Lesion Categories and Factors Associated With Fecal Immunochemical Test Positivity
Results of multivariate analysis of FIT positivity in association with lesion category and patient characteristics are presented in Table 4 . This analysis was adjusted for patients' age, gender, smoking status, medication use (antiplatelet agent or NSAIDs), body mass index, cecal intubation, and bowel cleansing level. The likelihood of FIT positivity among those with SSA/P was not different compared with those without any finding at colonoscopy, with the adjusted odds ratio (aOR) (95% CI) of 1.61 (0.76-3.40), 1.48 (0.53-4.14), and 1.93 (0.69-5.39), respectively, at those 3 cutoffs. FIT positivity rate was less in patients with SSA/P than in patients with adenoma, and the aOR (95% CI) was 0.32 (0.14-0.69), 0.21 (0.07-0.61), and 0.25 (0.09-0.74) at those 3 cutoffs. Compared with advanced adenoma, large SSA/P was associated with lower FIT positivity rate at the cutoff of 15 mg/g, with aOR of 0.30 (95% CI, 0.10-0.90). The results were similar when patients with synchronous SSA/P and adenoma were compared with those with conventional adenoma.
Positive Predictive Value and Number Needed for Endoscopy
The PPVs of FIT and NNScope in detecting certain lesion categories are shown in Supplementary Table 1 . The NNScope to detect any adenoma or SSA/P was 2.2, 2.0, Subjects with synchronous conventional adenoma. b Comparison of FIT sensitivity for proximal vs distal lesions at cutoff of 10 mg/g: P ¼ .003 for SSA/P only, P < .001 for all SSA/P, P ¼ .001 for large SSA/P only, and P < .001 for large SSA/P. 
Discussion
The present study explored the sensitivity of FIT for detecting SSA/P compared with the sensitivity for detecting conventional adenoma in an asymptomatic screening population. Results of the present study showed that FIT exhibits lower sensitivity for detecting SSA/P compared with its demonstrated sensitivity for detecting conventional adenoma.
Despite the better performance of FIT over gFOBT for detecting CRC and the demonstration of its effectiveness in reducing CRC mortality, interval cancers are identified in every screening program and may affect the overall effectiveness of the specific screening programs. 18, 19 Therefore, it is important to understand the performance of FIT for SSA/P, which is a precancerous lesion and a significant contributor to interval CRC. The data presented herein demonstrated that FIT has a significantly lower sensitivity for SSA/P compared with its sensitivity for conventional adenoma. Even for large SSA/P, the sensitivity was still lower than that for advanced adenoma, even after adjusting for lesion size and other factors. These findings add to the current evidence on FIT sensitivity for SSA/P.
The low sensitivity of FIT for SSA/P may be explained in several ways. First, observation of the vascular density of SSA/P by using image-enhanced endoscopy reveals distinct differences between SSA/P and conventional adenoma. The latter has a dense microvascular network in the mucosal layer, whereas the former has a thick but more diffuse distribution of submucosal ectatic vessels. This thicker and more diffuse vasculature is considered less likely to bleed as a result of friction between fecal material and the mucosal surface, which is the proposed cause of occult blood in the stool. Second, most SSA/Ps are located in the proximal colon, and it is likely that the amount of blood in the stool may decrease as the stool travels toward the distal colon. This was consistent with our previous study, which demonstrated that neoplasms located proximally are more likely to yield false-negative results with FIT. 13 Third, the non-polypoid morphology of SSA/P may also contribute to the false-negative results of FIT. In a recent study, Risio et al 20 reported that ischemia-related luminal bleeding, which is probably caused by the more common torsion of the polyp stalk in polypoid lesions, was significantly more frequent in advanced adenoma detected by FIT compared with that detected by endoscopy. Nearly 60% of SSA/Ps are located proximally and appear as flat morphology, and FIT has been shown to have limitations in detecting flat neoplasms in the proximal colon. 13 The clinical implications of such low FIT sensitivity for SSA/Ps deserve careful consideration. Consider, for example, that a stool-based CRC screening strategy is conducted via repetitive testing at fixed intervals. The low single-test sensitivity of FIT for SSA/P does not represent lower program sensitivity for cancer if public adherence to repetitive screening is good. Thus, it is essential to stress the importance of repetitive screening. According to reports from current population-screening programs, however, screening uptake usually declines in subsequent rounds compared with that in the prevalent screening round. 21, 22 Therefore, approaches aimed at improving single-test sensitivity may be helpful, but the balance between cost and effectiveness should be seriously evaluated. Also important in the present study is that the sensitivity of FIT for detecting large SSA/Ps is higher than that reported by Imperiale et al 10 (10.5% vs 5.1%). Although such a difference cannot be clearly explained, the different brands of FIT kits that are used in these 2 studies may play some role. Our previous study revealed that even when using the same hemoglobin cutoff, different FIT kits might perform differently in terms of detecting neoplasms. 19 Several approaches can be considered to increase the detection of SSA/Ps by stool-based tests. One approach is to add extra stool samples, which may be helpful for improving single screening round sensitivity. Currently, the required number of stool samples varies between programs, and the optimal number is not known. Although previous studies have shown better detection for advanced adenoma by 2-sample FIT compared with 1-sample FIT, no data are currently available regarding the applicability of 2-sample FIT for detecting SSA/Ps. 23 Another approach may involve screening tests that target other biomarkers to help compensate for the deficit of FIT in SSA/P detection. The sensitivities of stool DNA tests for large SSA/Ps were reported to vary from 42.4% to 56.6%, which is remarkably higher than that demonstrated in the present study.
9,10,24 Therefore, applying a stool DNA test may be a rational solution to overcome the limitations of FIT-based screening for detecting SSA/Ps. Despite the advantage of better detection of SSA/Ps by the multi-target stool DNA test, the high cost and unclear population adherence to this test hinder its use in large-scale organized screening programs currently.
The adenoma detection rate in this study cohort was 27.1%, combining 1.4% for SSA/P, 5.5% for advanced adenoma, and 20.2% for non-advanced adenoma. The range of adenoma detection rates among our endoscopy staffs was 23.7%-32.1% during the study period. This prevalence is consistent with previous studies conducted in Taiwan. 7, 25 The relatively lower prevalence of colorectal neoplasm in our study compared with that in the Western studies is probably due to regional epidemiology difference and partially due to the healthier population that was participating in the health checkups program in our cohort.
The present study has several strengths, beginning with the fact that our study population was representative of the general Chinese screening population. The prevalence of SSA/P in our population was 1.4%, and this result was consistent with previous studies. 26, 27 The present study included asymptomatic subjects who received screening colonoscopy as part of a general health checkup not specific for CRC screening, therefore minimizing the possibility of bias. Moreover, positivity rates of 10.4%, 6.2%, and 5.0% at cutoffs of 10, 15, and 20 mg/g, respectively, are within the range of FIT positivity reported by several FIT-based screening programs or trials in the general population, 3, 18, 28 which again supports our cohort as representative of the general population. In addition, the quantitative FIT results in this study enabled us to conduct a comprehensive analysis at different FIT cutoffs and to stratify analysis by different lesion categories. We also conducted an analysis that included patients with synchronous conventional adenoma. Thus our study provides additional information that is useful in the clinical setting. We also reviewed histology of each serrated polyp centrally by single experienced gastrointestinal pathologist to avoid interobserver variation.
Nevertheless, this study was not without limitations, including that the study cohort was limited to ethnic Chinese subjects, and this may affect the generalizability of the study findings to other populations. Furthermore, subjects who volunteered for health checkups were included in this study, and this may lead to a selection bias toward individuals of a relatively high socioeconomic status and healthy lifestyle. In addition, we have only a paucity of cases with SSA/P with dysplastic change; therefore, we were unable to evaluate whether FIT positivity would increase in the presence of advanced histology. Furthermore, we did not evaluate the impact of multiple SSA/Ps on FIT positivity, which may have been helpful because previous studies have shown that synchronicity of conventional adenoma is associated with increased sensitivity of FIT. 29 In conclusion, the present study demonstrated low sensitivity of FIT for SSA/P detection. The impact of this finding on the effectiveness of FIT-based CRC screening programs requires further study.
